Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

303 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.
De Bruycker A, Spiessens A, Dirix P, Koutsouvelis N, Semac I, Liefhooghe N, Gomez-Iturriaga A, Everaerts W, Otte F, Papachristofilou A, Scorsetti M, Shelan M, Siva S, Ameye F, Guckenberger M, Heikkilä R, Putora PM, Zapatero A, Conde-Moreno A, Couñago F, Vanhoutte F, Goetghebeur E, Reynders D, Zilli T, Ost P. De Bruycker A, et al. Among authors: ost p. BMC Cancer. 2020 May 12;20(1):406. doi: 10.1186/s12885-020-06911-4. BMC Cancer. 2020. PMID: 32398040 Free PMC article. Clinical Trial.
Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
Steuber T, Jilg C, Tennstedt P, De Bruycker A, Tilki D, Decaestecker K, Zilli T, Jereczek-Fossa BA, Wetterauer U, Grosu AL, Schultze-Seemann W, Heinzer H, Graefen M, Morlacco A, Karnes RJ, Ost P. Steuber T, et al. Among authors: ost p. Eur Urol Focus. 2019 Nov;5(6):1007-1013. doi: 10.1016/j.euf.2018.02.015. Epub 2018 Mar 10. Eur Urol Focus. 2019. PMID: 29530632
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial.
Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Hölscher T, Gut P, Polat B, Hildebrandt G, Müller AC, Plasswilm L, Papachristofilou A, Schär C, Sumila M, Zaugg K, Guckenberger M, Ost P, Reuter C, Bosetti DG, Khanfir K, Gomez S, Wust P, Thalmann GN, Aebersold DM; Swiss Group for Clinical Cancer Research (SAKK). Ghadjar P, et al. Among authors: ost p. Eur Urol. 2021 Sep;80(3):306-315. doi: 10.1016/j.eururo.2021.05.033. Epub 2021 Jun 14. Eur Urol. 2021. PMID: 34140144 Clinical Trial.
Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial.
Fonteyne V, Dirix P, Van Praet C, Berghen C, Albersen M, Junius S, Liefhooghe N, Noé L, De Meerleer G, Ost P, Villeirs G, Verbeke S, De Maeseneer D, Rammant E, Verghote F, Elhaseen E, De Man K, Decaestecker K. Fonteyne V, et al. Among authors: ost p. Eur Urol Focus. 2022 Sep;8(5):1238-1245. doi: 10.1016/j.euf.2021.11.004. Epub 2021 Dec 8. Eur Urol Focus. 2022. PMID: 34893458 Free article. Clinical Trial.
Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study.
Fonteyne V, Danckaert W, Ost P, Berghen C, Vandecasteele K, Vanneste B, Rans K, Liefhooghe N, Wallaert S, Paelinck L. Fonteyne V, et al. Among authors: ost p. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231154088. doi: 10.1177/15330338231154088. Technol Cancer Res Treat. 2023. PMID: 37016933 Free PMC article. Clinical Trial.
Microbiome and metabolome dynamics during radiotherapy for prostate cancer.
Danckaert W, Spaas M, Sundahl N, De Bruycker A, Fonteyne V, De Paepe E, De Wagter C, Vanhaecke L, Ost P. Danckaert W, et al. Among authors: ost p. Radiother Oncol. 2023 Dec;189:109950. doi: 10.1016/j.radonc.2023.109950. Epub 2023 Oct 10. Radiother Oncol. 2023. PMID: 37827280
303 results